SPX4,026.12-1.14 -0.03%
DIA343.52+1.57 0.46%
IXIC11,226.36-58.96 -0.52%

--Citigroup Adjusts Price Target on Fate Therapeutics to $80 From $87, Maintains Buy Rating

--Citigroup Adjusts Price Target on Fate Therapeutics to $80 From $87, Maintains Buy Rating

MT Newswires · 11/16/2022 05:08

Please log in to view news